Actively Recruiting
Immunotherapy for Hepatocellular Carcinoma
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-04-10
11000
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
CONDITIONS
Official Title
Immunotherapy for Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older.
- Diagnosed with hepatocellular carcinoma by pathology or imaging.
- Assessed by researchers as potentially benefiting from immunotherapy-based combination treatments.
- For patients previously treated under this protocol, a full pre-treatment assessment including demographics, tumor history, medical history, and baseline imaging is required.
- Voluntarily willing to participate in the study.
You will not qualify if you...
- Pregnant or lactating women.
- Other conditions as determined by the investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
X
Xuehao Wang, professor
CONTACT
Y
Yongxiang Xia, professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here